Scientists test RSV vaccine to boost immune memory
NCT ID NCT07618325
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will test a new RSV vaccine in 60 adults aged 20 and older. Researchers want to understand how the vaccine triggers the immune system to create strong antibodies and memory T cells. The goal is to learn how to make RSV vaccines more effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)
- What this could lead to
- If successful, this could help develop a more effective RSV vaccine by revealing how the immune system builds long-lasting protection.
- What could go wrong
- This is an early-stage study with only 60 participants, focused on immune markers rather than disease prevention. The vaccine may not produce strong or lasting immunity in real-world settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One shot, two viruses? new mRNA vaccine targets RSV and hMPV
- New mRNA vaccine aims to shield against RSV
- Massive RSV vaccine study uses real-world data to see if shots prevent severe illness
- New RSV vaccine aims to shield adults from severe respiratory infection
- New study tracks RSV in pregnant women and their babies
- One shot to stop RSV: landmark trial for indigenous kids